Temporal Changes In Innate And Adaptive Immunity During Sepsis As Determined By Elispot
Jacqueline Unsinger,Dale Osborne,Andrew H. Walton,Ethan Han,Lauren Sheets,Monty B. Mazer,Kenneth E. Remy,Thomas S. Griffith,Mahil Rao,Vladimir P. Badovinac,Scott C. Brackenridge,Isaiah Turnbull,Philip A. Efron,Lyle L. Moldawer,Charles C. Caldwell,Richard S. Hotchkiss
DOI: https://doi.org/10.1097/shk.0000000000002377
2024-07-19
Shock
Abstract:Sepsis, a life-threatening organ dysfunction caused by a dysregulated host response to infection, is the most common cause of mortality in intensive care units in the United States ( 1 ). Both pro- and anti-inflammatory processes are initiated simultaneously in sepsis, and their intensity and duration vary throughout the course of the disease ( 2–4 ). The lack of an effective means to evaluate the intensity of the host immune status in sepsis in a rapid quantitative method has severely hampered the development of novel immune therapies that could potentially improve outcomes. This absence of a method to immune endotype septic patients is also undoubtedly a contributing factor in the failure of numerous drug therapy trials in sepsis. For example, administration of corticosteroids to patients in refractory septic shock is likely to be beneficial in the subset of patients who are in the more hyperinflammatory phase but may well be detrimental to patients who are in the more immunosuppressive phase of the disorder ( 5,6 ). Although there have been considerable efforts to develop methods to immune endotype septic patients (e.g., using transcriptomics), these methods often do not reflect the functional state of host immunity, lack dynamic range, and are more indicative of molecular processes rather than host immunity. Additionally, the data may not be available in a clinically relevant timeframe. We also believe that the relative balance between pro- and anti-inflammatory processes is dynamic over the course of illness, so methods that only allow sampling at a single time point may be of limited utility in guiding therapeutics.
surgery,peripheral vascular disease,hematology,critical care medicine